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Active speciﬁc immunotherapy, using vaccines with autologous tumour cells and BCG, signiﬁcantly reduces the rate of tumour
recurrence in stage II colon cancer patients, while no clinical beneﬁt has yet been observed in stage III patients. Adjuvant
treatment with 5-Fluorouracil/Leucovorin is now considered standard therapy for stage III colon carcinoma and results in an
absolute survival beneﬁt of approximately 10%. Yet, the 5-year overall survival rate of stage III colon cancer patients is only
40–50%. Combining chemotherapy and immunotherapy might improve prognosis for stage III patients, especially when
considering that active speciﬁc immunotherapy and chemotherapy have shown synergistic effects in pre-clinical tumour
models. We performed a phase II study with 56 patients, using the combination of active speciﬁc immunotherapy and
chemotherapy as an adjuvant therapy in stage III colon cancer patients to assess the inﬂuence of 5-Fluorouracil/Leucovorin on
anti-tumour immunity induced by autologous tumour cell vaccinations. Anti-tumour immunity was measured before and after
chemotherapy by means of delayed type hypersensitivity reactions, taken 48 h after the third and the fourth vaccination. We
also investigated the toxicity of this combined immuno-chemotherapy treatment. Delayed type hypersensitivity reactions
before chemotherapy had a median size of 20.3 mm, while after chemotherapy delayed type hypersensitivity size was
18.4 mm (P=0.01), indicating that chemotherapy hardly affected anti-tumour immunity. The severity of ulcers at the BCG
vaccination sites was comparable to previous studies. In 30% of the patients grade III or grade IV chemotherapy related
toxicity was seen; this is comparable to what is normally observed after adjuvant chemotherapy alone. This study shows that
the active speciﬁc immunotherapy-induced anti-tumour immune response is only minimally impaired by consecutive
chemotherapy and that the combined treatment of stage III colon cancer patients with active speciﬁc immunotherapy and 5-
Fluorouracil/Leucovorin does not cause unexpected toxicity.
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Colon cancer is one of the most prevalent malignancies in the
industrialised world, with approximately 240000 new cases diag-
nosed each year in the USA and Western Europe. When colon
cancer is detected early, in stages I or II (Dukes A or B), the 5 year
survival rate with surgery alone is 60–90%, depending on the
depth of invasion of the tumour into the bowel wall. When the
cancer has spread to the regional lymph nodes, or stage III (Dukes
C), the 5 year survival rate is 25–60%. Important prognostic
factors in stage III colon carcinoma include the number of positive
nodes, extra-nodal growth, invasion of adjacent organs, grade of
histologic differentiation and post-operative CEA level. When
distant metastases are diagnosed, stage IV (Dukes D), the 5 year
survival rate is less than 5% (Cohen et al, 1997).
Currently most patients with stage III colon carcinoma receive
an adjuvant treatment with 5-Fluorouracil (5-FU) and Leucovorin.
Several large studies have shown that this chemotherapeutic regi-
men reduces the relative death rate of stage III patients by 30–
40% (Wolmark et al, 1993; Francini et al, 1994; Moertel et al,
1995; IMPACT investigators, 1995; O’Connell et al, 1997).
Our efforts have focused on active speciﬁc immunotherapy
(ASI), that makes use of the patient’s own tumour to elicit a
long-term anti-tumour immune response, as adjuvant therapy.
Recently, we demonstrated in a randomised phase III study that
adjuvant treatment with ASI, using autologous tumour cells and
BCG, resulted in a signiﬁcant reduction in the rate of recurrence
in stages II and III colon cancer patients (Vermorken et al,
1999). Results were most pronounced in stage II patients, whereas
in stage III colon cancer patients no clinically signiﬁcant beneﬁt
was observed. The absence of a clinical effect in stage III colon
cancer might be explained by the lack of statistical power of this
study, as only 83 stage III patients were included. Furthermore,
the residual tumour load in stage III patients is probably larger
than in stage II patients, which could be relevant since it is known
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(Hanna et al, 1979; Tamura et al, 1997; Baars et al, 2000).
In pre-clinical models ASI and chemotherapy were shown to
have a synergistic anti-tumour effect. Apart from the capacity to
directly destroy micro-metastases, ASI has been demonstrated to
disrupt the characteristically compact structure of metastatic foci,
enabling chemotherapy to reach deeper into the cancer tissue. In
addition, chemotherapeutically killed tumour cells will disperse
large amounts of intracellular antigens to an awaiting immune
system. Furthermore, chemotherapy reduces the tumour burden,
thereby increasing the chances of ASI subsequently eliminating
the residual malignant cells (Hanna et al, 1982).
Several studies have demonstrated that the size of Delayed Type
Hypersensitivity reactions (DTH) after autologous tumour cell
vaccinations correlates strongly with recurrence and survival of
cancer. The presence of a DTH response to tumour cells, 48 h after
the vaccination regimen, is a measure of immunogenicity and
reﬂects the adequacy of the vaccination and the general immune
status of the patient. So far, DTH has been the only suitable para-
meter for the evaluation of anti-tumour immunity and the best
early predictor of clinical efﬁcacy of vaccination therapies (McCune
et al, 1990; Harris et al, 2000; Baars et al, 2000; Clay et al, 2001).
Different strategies to test anti-tumour immunity have been
investigated by other groups, often with disappointing results (Clay
et al, 2001). Theoretically, peptide/MHC-tetramer staining of
lymphocytes, with the purpose of detecting antigen speciﬁc cyto-
toxic T-lymphocytes, is the optimal method to evaluate the
development of anti-cancer immunity (Altman et al, 1996).
However, only a few tumour antigens have been identiﬁed for
colon carcinoma, and it is still elusive which cancer antigens are
most important for the development of a clinically relevant
immune reaction. Moreover, studies investigating the correlation
between the development of tetramer-positive CTL’s and clinical
prognosis have shown contradictory results (Lee et al, 1999; Fong
et al, 2001; Haanen et al, 2001). Therefore, at this moment we
consider the DTH response to be the most reliable parameter for
the evaluation of the development of an immunological anti-
tumour response in colon cancer patients after active speciﬁc
immunotherapy with autologous tumour cells.
In preparation for a large randomised trial we investigated in
this study whether the combined anti-cancer treatment with
chemotherapy and ASI can be safely administered in colon cancer
patients and whether 5-FU/Leucovorin affects the efﬁcacy of ASI.
Endpoints were toxicity and the size of DTH to autologous tumour
cell vaccinations before and after chemotherapy.
PATIENTS AND METHODS
Patients
Patients undergoing a colon resection for a histologically proven or
clinically suspected adenocarcinoma of the large bowel were
selected. Distant metastases were excluded by means of pre-opera-
tive chest X-rays and liver ultrasound or CT-scanning. Patients
with stage III colon cancer were eligible for this clinical trial. A
WHO performance status of 0 or 1 was required. Patients with
rectal cancer, perforated tumours, Crohn’s disease, Ulcerative Coli-
tis, previous malignancies, using immune suppressive medication,
as well as pregnant and lactating women were excluded. Pathology
reports were routinely reviewed on all patients. All patients gave
written informed consent.
Vaccine preparation
Six Dutch hospitals participated in this study. Surgery was
performed in the referring hospital. Immediately after surgery part
of the tumour tissue not required for pathological examination was
excised and transferred to the vaccine production laboratory of the
Vrije Universiteit Medical Center, Amsterdam. The tumour was
dissociated as previously described (Hanna et al, 1979; Peters et
al, 1979). After this procedure viability was tested using trypan
blue. Cells were aliquotted (15–20610
6 viable cells per vial) and
cryopreserved using a linear freezer. Vials were stored in liquid
nitrogen until vaccination. For each patient four vaccines were
produced.
Vaccination procedure
Vaccination started 4–5 weeks after surgery to minimise the possi-
ble immune suppressive inﬂuence of surgery and anaesthesia. On
the day of vaccination, after thawing, cells were counted and viabi-
lity was assessed. For every vaccine 10
7 viable autologous tumour
cells were irradiated (200 Gy) and to the ﬁrst two vaccines 10
7
viable fresh-frozen BCG organisms were added. Vaccines were
administered intra-cutaneously near sites of regional lymph nodes.
The ﬁrst two vaccines, containing BCG, were injected on the right
and left anterior thigh respectively, at an interval of 1 week (Figure
1). In the following week the third vaccine was given in the right
upper arm. Eight months after the third vaccination, and at least
4 weeks after the last cycle of chemotherapy, a booster vaccination
was administered in the left upper arm.
Chemotherapy
Two weeks after the third vaccination, i.e. about 9 weeks after
surgery, the ﬁrst cycle of chemotherapy was given. Chemotherapy
was administered in the referring hospital and normally consisted
of 5-FU 425 mg m
2 and Leucovorin 20 mg m
2 as a bolus injection
for 5 consecutive days, every 4 weeks for six cycles. In one of the
participating hospitals, treating 12 of the patients described here,
the chemotherapy was given in a 1 day per week schedule for 6
months, using 5-FU 600 mg m
2 and Leucovorin 20 mg m
2.
Patient charts were audited for all patients. Toxicity of the
chemotherapy was measured using the National Cancer Institute
Common Toxicity Criteria for Cancer Clinical Trials, version 2.0.
DTH assessment
Response to the vaccines not containing BCG was measured by the
size of induration 48 h after injection. Induration was assessed by
the pen method (Sokal, 1975). For measurement of induration a
line was drawn with a pen from 1 to 2 cm away from the margin
of the skin test reaction towards the lesion. The pen is held at a 458
angle and moderate pressure is applied. The pen is advanced until
resistance is met, indicating the edge of the area of induration. This
procedure is performed in four directions. In this study the average
of the two perpendicular diameters was used as the size of indura-
tion.
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Week: 0              4     5    6     8        12       16       21       26      31      35
Vaccines 1 and 2: 107 autologous tumour cells + 107 BCG organisms
Vaccines 3 and 4: 10
7 autologous tumour cells
Chemotherapy: 5-FU 425 mg m2 day 1–5 + Leucovorin 20 mg m2
ASI ASI
vaccine 4 vaccine 1 vaccine 3
vaccine 2 surgery
chemotherapy
Figure 1 The treatment schedule that was used in this trial, showing that
chemotherapy was preceded by 3 weekly tumour cell vaccinations. One
month after the last gift of 5-FU a booster vaccination was administered.
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Wilcoxon’s matched pairs test was used for analysing differences
between DTH-values. Calculations were made with SPSS 9.0 soft-
ware.
RESULTS
Patients
Between March 1996 and December 1999 colon tumours of 104
stage III patients were processed. For 78 (75%) patients adequate
vaccines could be produced. Fifty-six patients received the autolo-
gous vaccines of which 53 had ﬁnished their immunisation
procedure at follow-up in June 2000. Reasons for not receiving
vaccination therapy although having a stage III tumour were refu-
sal of the patient to participate in this clinical trial (n=11),
postoperative complications (n=4), the use of corticosteroid medi-
cation (n=2), alcoholic liver insufﬁciency (n=1), ulcerative colitis
(n=1) and advanced age (n=3).
The median follow-up time was 21.7 months. Patient character-
istics of all vaccinated stage III patients are shown in Table 1.
Vaccine quality
The median weight of tumour received by our laboratory was
6.45 g (range 1.61–19.47 g). The median yield of tumour cells
per gram of tissue was 17.9610
6 (range 4.0–39.7610
6).
Side effects
In all patients ulcers developed at the site of the ﬁrst and second
vaccination, normally after a period of 2–3 weeks. Size of these
ulcers ranged from 1 to 3 cm in diameter. All ulcers healed spon-
taneously after a median time of 2.6 months (range 0.8–7.1
months). Twenty-two patients (39%) noticed a fever and ﬂu-like
symptoms within 48 h after vaccination and eight patients (14%)
mentioned tender regional lymph nodes during several days follow-
ing the vaccinations. In Table 2 the toxicity occurring during
chemotherapy treatment is presented. Seventeen patients (30%)
experienced grade III or grade IV toxicity. A dose reduction was
required in 20 patients (36%), of which eight (14%) could not
ﬁnish all scheduled cycles due to toxicity.
One patient, a 60-year old male, developed grade IV mucositis
and a paralytic ileus after the ﬁrst cycle of chemotherapy. Colono-
scopy showed diffuse ischaemia and ulcers, while the surgical
anastomosis was intact. Shortly thereafter, a multiple organ failure
syndrome developed and the patient died. Seven blood cultures
showed no bacterial growth. Autopsy was not performed. Death
of this patient is considered to result from toxicity of 5-FU.
Delayed type hypersensitivity reaction (DTH)
In each patient some form of local reaction was seen, 48 h after the
third and fourth vaccinations. This consisted of erythema and
induration. As shown in Figure 2, the mean diameter of the
induration after the third vaccination was 20.3 mm (s.d. 6.4). After
the fourth vaccination this was 18.4 mm (s.d. 10.9). These values
showed a statistically signiﬁcant difference (P=0.01). In one patient
ulceration occurred after the third vaccination, healing sponta-
neously within 3 weeks. The same was observed in another
patient after the fourth vaccination.
DISCUSSION
This is the ﬁrst study using the combined treatment of chemother-
apy and autologous tumour cell vaccinations for the adjuvant
treatment of colon cancer. The most important result presented
here is that the DTH-reaction after the fourth autologous tumour
cell vaccination is still strong, despite the fact that 5-FU/Leucovorin
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Table 1 Patient characteristics
Vaccinated stage III patients
(n=56)
Median age at start of ASI treatment 64.3 years
(range) (25.5–78.8)
Sex
Male 26 (46%)
Female 30 (54%)
Location of primary tumour
Right colon 18 (33%)
Left colon 38 (67%)
Depth of invasion
T1 0
T2 6 (10%)
T3 43 (80%)
T4 7 (10%)
Stage of differentiation
Well 12 (21%)
Moderate 33 (59%)
Poor 11 (20%)
Number of positive lymph nodes
0 1 (2%)
1–3 35 (62%)
4–7 15 (23%)
58 5 (9%)
Extra-nodal growth 24 (43%)
Table 2 Moderate and severe toxicity in vaccinated stage III patients
(n=56)
Toxicity Grade II (%) Grade III (%) Grade IV (%)
Diarrhoea 3 (5) 5 (9) 3 (5)
Nausea 6 (11) 1 (2) 0
Vomiting 4 (7) 1 (2) 0
Ileus 0 0 2 (4)
Mucositis 5 (9) 4 (7) 1 (2)
Febrile neutropenia 0 2 (4) 0
Deep vein thrombosis 0 1 (2) 0
Conjunctivitis 1 (2) 0 0
Skin rash 1 (2) 0 0
DTH-reaction after 3rd and 4th vaccination
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Figure 2 The diameter of the Delayed Type Hypersensitivity Reactions
after the third and the fourth autologous tumour cell vaccination, measured
48 h after injection.
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This is important because DTH-reactions indicate the development
of speciﬁc cellular immunity and correlate strongly with survival
(McCune et al, 1990; Baars et al, 2000; Harris et al, 2000). A
recently published study with autologous colon tumour vaccines
has shown that DTH-reactions with a diameter exceeding 10 mm
should be considered to reﬂect successful vaccination therapy and
predict relatively good survival rates (Harris et al, 2000).
Thus, the chemotherapy regimen used in our protocol seems not
to have a clinically important suppressive inﬂuence on the anti-
tumour immunity induced by vaccination with tumour cells.
However, other types of chemotherapy might have a more
pronounced negative effect on anti-tumor immunity than 5-FU,
so future combinations of immune therapy and chemotherapy will
have to be carefully tested too, before being applied on large scale
in a clinical setting.
Toxicity after the tumour cell vaccinations, consisting of ulcers
after the ﬁrst two injections and low grade fever in a minority of
patients, was comparable to what we observed in our previous
study, when no chemotherapy was used (Vermorken et al, 1999).
Side effects of the chemotherapy regimen were considerable,
with grade III or grade IV toxicity occurring in 30% of patients.
Gastrointestinal toxicity and mucositis were most prominent.
One patient died shortly after receiving the ﬁrst course of
chemotherapy. Clinically, the most likely cause of death in this
patient was acute mesenteric ischaemia, but this was not proven
since an autopsy was not performed. Vascular toxicity is a known
side-effect of 5-FU/Leucovorin, most often presenting like coronary
vasospasms, but solitary bowel ischaemia has also been described
(Fata et al, 1999). The precise mechanisms behind these circulatory
changes are unknown (Robben et al, 1993). Overall, in this study
the toxicity seen after chemotherapy was not different from the
toxicity of previous studies using 5-FU/Leucovorin, and thus
appears not to be inﬂuenced by the immunotherapy given in our
clinical trial.
In conclusion, this study shows that the ASI-induced anti-
tumour immune response is only minimally impaired by consecu-
tive 5-FU/Leucovorin and that the combined treatment of stage III
colon cancer patients with ASI and chemotherapy does not cause
unexpected toxicity. Therefore, we recently started a randomised
international phase III study investigating the efﬁcacy of ASI
combined with 5-FU+Leucovorin as an adjuvant treatment for
stage III colon cancer patients.
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